Kane Biotech Inc. KNE
TSXV · Canada · Commercial Services
CAD 0.03000.00 (0.00%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane’s commercial progress, clinical relevance and operational prioritiesWINNIPEG, Manitoba, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will host a virtual Commercial Update on
Agreement broadens access to revyve® advanced wound care products through an established Canadian medical supply distributorWINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) is pleased to announce that it has entered into a non-exclusive distribution agreement with Ontario Medical Supply Inc. ("OMS"), an Ottawa-based medical supply distributor serving the Canadian market. U.S. FDA 510(k) cleared and Health Canada approv
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results. Second Quarter 2026 Financial Highlights: Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including init
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.